Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Xenetic Biosciences (XBIO) Stock Price & Analysis

347 Followers

XBIO Stock Chart & Stats

$1.87$0.01(0.27%)
At close: 4:00 PM EST
$2$3$4Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$1.76 - $1.97
52-Week Range
$1.58 - $4.94
Previous Close
$1.87
Volume
N/A
Average Volume (3M)
25.00K
Market Cap
$4.38M
Enterprise Value
$204.83K
Total Cash (Recent Filing)
$6.47M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
0.60
Next Earnings
May 13, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Gross Margin

Strong top-line expansion and high reported gross margins indicate that XBIO is generating meaningful revenue growth with favorable direct economics. If sustained, this combination can support reinvestment in development programs and improve operating leverage as the business scales.

Debt-free Balance Sheet

A debt-free balance sheet reduces interest expense, refinancing exposure, and fixed financial obligations while preserving flexibility for research and corporate development. This provides a relatively stronger financial foundation than leveraged peers, even though operating losses remain significant.

Broader Clinical Pipeline

The proposed combination could materially broaden XBIO beyond its historical platform focus by adding multiple clinical programs across critical care, autoimmune disease, transplantation, and oncology. A wider pipeline creates more opportunities for durable clinical and strategic progress.

Bears Say

Persistent Operating Losses

Deeply negative profitability shows that current revenue is not yet sufficient to cover operating costs, leaving earnings dependent on future program progress and commercialization. Until scale or product economics improve, the company remains exposed to prolonged losses and uncertain earnings power.

Ongoing Cash Burn

Persistent negative operating and free cash flow means XBIO is not currently self-funding its activities. Continued cash consumption can constrain development choices and make external financing necessary, increasing dependence on capital markets before operations become cash generative.

Dilution And Transaction Execution Risk

The proposed all-stock transaction would substantially shift ownership and control toward Santersus investors, potentially diluting existing holders. Its benefits also depend on approvals, exchange-ratio decisions, listing compliance, and successful integration, creating material execution uncertainty.

Xenetic Biosciences News

XBIO FAQ

What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $1.58 and its highest was $4.94 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $4.38M.
When is Xenetic Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on Aug 07, 2026. The company reported -$0.41 earnings per share for the quarter.
Is Xenetic Biosciences overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,343,181 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -$0.41 in its last earnings report. Following the earnings report the stock price went up 0.268%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology